DEVICES AND METHODS FOR OPHTHALMIC DRUG DELIVERY

• US 20080145406A1
• Filed: 11/08/2007
• Published: 06/19/2008
• Est. Priority Date: 12/18/2006
• Status: Abandoned Application

• Current Assignee: Alcon Research Limited (Nestle SA)
• Original Assignee: Alcon Manufacturing Limited (Alcon Incorporated)
• Inventors: Chowhan, Masood A., Asgharian, Bahram
• Application Number:
  US11/936,842
• Publication Number:
  US 20080145406A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61F 9/0017 implantable in, or in contact with, the eye, e.g. ocular inserts
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/06 Antiglaucoma agents or miotics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/00 Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 5/00 Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 7/02 Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Disclosed are ophthalmic drug-delivery devices, comprising a body having a proximal end and a distal end, wherein the body includes a styrene elastomer matrix and a drug in contact with the matrix. Also disclosed are methods of treating or preventing an eye disease in a subject, that involve contacting an eye of the subject with an ophthalmic drug delivery device comprising a body having a proximal end and a distal end, wherein the body comprises a styrene elastomer matrix and a drug in contact with the matrix, wherein release of the drug from the device occurs over time following contacting of the device with the eye of the subject.

Claims

1. An ophthalmic drug-delivery device comprising:

a body configured to be inserted into a subject in the proximity of an eye of the subject, the body including a styrene elastomer matrix; and

a drug in contact with the matrix.

2. The device of claim 1, wherein the body includes a linearly-shaped portion.

3. The device of claim 1, wherein the body has a non-linear shape.

4. The device of claim 1, wherein the body includes a flange-shaped proximal end.

5. The device of claim 4, wherein the flange-shaped proximal end includes one or more holes for suturing the device to the eye.

6. The device of claim 1, wherein the body has a length of about 5 mm to about 40 mm.

7. The device of claim 5, wherein the body has a length of about 10 mm to about 30 mm.

8. The device of claim 6, wherein the body has a diameter of about 0.1 mm to about 5 mm.

9. The device of claim 1, wherein the styrene elastomer matrix comprises a copolymer selected from the group consisting of styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), styrene-isoprene-butadiene-styrene block copolymer (SIBS), styrene-ethylene-butylene-styrene block copolymer (SEBS), and styrene-ethylene-propylene-styrene block copolymer (SEPS).

10. The device of claim 9, wherein the styrene elastomer matrix is SIBS.

11. The device of claim 1, wherein the drug is selected from the group consisting of an anti-angiogenesis agent, an anti-glaucoma agent, an anti-infective agent, a nonsteroidal anti-inflammatory agent, a growth factor, an immunosuppressant agent, and an anti-allergic agent.

12. The device of claim 11, wherein the active agent is an anti-angiogenesis agent.

13. The device of claim 12, wherein the anti-angiogenesis agent is anecortave acetate, 4,9(11)-pregnadien-17α

,21-diol-3,20 dione, bevacizumab, ranibizumab, pegaptanib, or a receptor tyrosine kinase inhibitor (RTKi).

14. A method of treating or preventing an eye disease in a subject, comprising:

contacting an eye of the subject with an ophthalmic drug delivery device comprising;

a body configured to be inserted into the subject in the proximity of the eye, the body including a styrene elastomer matrix; and

a drug in contact with the matrix;

wherein the drug is released from the device over time following the contacting.

15. The method of claim 14, wherein the styrene elastomer matrix comprises a copolymer selected from the group consisting of styrene-isoprene-styrene block copolymer (SIS), styrene-butadiene-styrene block copolymer (SBS), styrene-isoprene-butadiene-styrene block copolymer (SIBS), styrene-ethylene-butylene-styrene block copolymer(SEBS), and styrene-ethylene-propylene-styrene block copolymer (SEPS).

16. The method of claim 14, wherein the subject is a human.

17. The method of claim 14, wherein the eye disease is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, chronic glaucoma, retinal detachment, sickle cell retinopathy, retinal neovascularization, subretinal neovascularization;

rubeosis irides, retinitis, choroiditis, posterior uveitis, neoplasms, retinoblastoma, pseudoglioma, neovascular glaucoma;

neovascularization resulting following a combined vitrectomy and lensectomy, vascular diseases, retinal ischemia, choroidal vascular insufficiency, choroidal thrombosis, neovascularization of the optic nerve, diabetic macular edema, cystoid macular edema, macular edema, retinitis pigmentosa, retinal vein occlusion, proliferative vitreoretinopathy, angioid streaks, retinal artery occlusion, and neovascularization due to ocular injury.

18. The method of claim 14, wherein the contacting comprising implanting the device in a subconjunctival and sub-Tenon'"'"'s location in the subject.

19. The method of claim 14, wherein the disease is age-related macular degeneration.

20. The method of claim 14, wherein the drug is anecortave acetate, 4,9(11)-pregnadien-17α

,21-diol-3,20 dione, bevacizumab, ranibizumab, or pegaptanib.